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Delegates from resource-rich nations attending
the 13th International AIDS Conference in
Durban, South Africa last month confronted the
unfathomable suffering HIV is causing in South
Africa and other developing nations.  However,
as desperate as the situation is in many of the
world’s poorest nations, it is in prisons where HIV
reigns.
Reflecting the unique role prisons and jails play in
the HIV pandemic, an entire conference sympo-
sium, entitled ’HIV Behind Bars’, was convened.
Oral and poster presentations at this symposium
provided a glimpse of life behind prison walls -
from rural sub-Saharan African jails to Latin
American penitentiaries, and painted a fuller pic-
ture of HIV in the nation with the greatest per
capita prison population, the US.
Concentrating an Epidemic
Presentations at Durban reinforced Dr. Jonathan
Mann’s observations that the most vulnerable
members of the population of any country are at
the highest risk for contracting HIV/AIDS (1).
Regardless of the country, prisons and jails con-
centrate HIV-infected and at-risk individuals.
Data regarding the prevalence of HIV/AIDS in
prisons in countries outside North America and
Europe have been scarce, however, reports at
the conference provided some new HIV preva-
lence information. The methods used for collect-
ing HIV prevalence data from correctional facili-
ties differed widely. Some studies relied on vol-
untary reporting (to surveyors or to prison health
care officials) which may significantly underesti-
mate the number of inmates who have HIV infec-
tion by at least 25% (2). Anonymous sero-
surveys are far more accurate than voluntary
reporting (3). 
Sub-Saharan Africa
Studies of the prevalence of HIV in African pris-
ons show rates ranging from 2.7% in a cross sec-
tional serostudy in Senegal (4) to 27% in Zambia
as determined by a voluntary questionnaire and
ELISA testing of 1,596 inmates (8 ). In the Côte
D’Ivoire, a random sample of 500 inmates in one
facility demonstrated a prevalence rate of HIV
infection of 28%, double that of the general pop-
ulation (4). 
These high HIV prevalence rates are not surpris-
ing, given the impact that HIV has had on this
region of the world. In sub-Saharan Africa
approximately 24.5 million people are living with
HIV infection - over two thirds of the world’s bur-
den of HIV. Over 11.5 million Africans have died
of AIDS, representing 83 percent of the total HIV-
related deaths worldwide. In several African
countries, the rate of HIV infection among adults
aged 15 to 49 exceeds 20% (5) and life
expectancies have plummeted to turn of the cen-
tury figures.
Asia
Eighteen percent (7 million) of the global popula-
tion of HIV-infection individuals live in South and
Southeast Asia. Limited information regarding
HIV prevalence rates in Asian correctional set-
tings is available (see Table 1). This is unfortu-
nate given that the Asian/Pacific region had the
second highest rate of new infections in 1998,
second only to Sub-Saharan Africa, and that this
region is predicted to be the next epicenter of HIV
infection (5). 
Latin America
HIV infection rates have doubled over the past
year in many sub-populations of Latin America.
On the Caribbean coast of Latin America, the
prevalence rate exceeds 16% among adults in
their 20s (5). According to the UNAIDS report,
heterosexual transmission is rapidly spreading
the disease throughout the region. A 1999 report
from Brazilian correctional facilities describes an
HIV prevalence of 16% among 631 inmates who
agreed to voluntary testing (6).  A cross-sectional
study of 693 inmates from three Brazilian prisons
revealed an HIV prevalence rate of 14%, with a
range of 11% (in one minimum-security facility) to
22% (in one maximum security facility) (7). 
Europe and the U.S.
European countries report a wide range of preva-
lence rates, ranging from 0.19% in anonymous
survey of 544 inmates in Athens, Greece (8) to
11% of inmates who volunteered for an anony-
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mous survey in Southeastern France (9) and
47% among a selected group of 639  injec-
tion drug using prisoners incarcerated in
LØon, Spain (10). In comparison, the nation-
wide average prevalence rate in the U.S. is
low, 2.3% overall. In the Northeastern U.S.,
however, anonymous serosurveys have
revealed  HIV infection rates ranging from 7
to 26% depending on the location of the cor-
rectional facility (rates are highest in New
York City, New York State, and New Jersey)
(11).
Gender
Distribution of HIV prevalence by gender is
reversed in correctional settings. In U.S.
prisons, incarcerated women are twice as
likely as men to have AIDS (11), in contrast
to the general US population where men are
almost four times as likely to have AIDS than
women (See HEPP News, April 2000) (12).
Several papers presented at the conference
from Brazil indicate women in that country
also exhibit higher rates of HIV infection than
men (7.2% versus 4.8%)(13, 14, 7).
Likewise, a study from India found a high
rate of 9.5% HIV prevalence among women
inmates, compared to 1.7% among men.
Ghante Nagaraj and colleagues attribute the
high rate of HIV among incarcerated women
to the fact that most are commercial sex
workers, a very high-risk occupation (15).
Likewise in the U.S., women are more likely
to be incarcerated for sex and drug crimes
known to be associated with increased risk
for HIV infection.
Risk Behaviors: Drug use
Obtaining data regarding in prison drug use
is challenging, but critical to our understand-
ing of the risk of HIV transmission inside
prisons. In several reports, investigators pre-
sented evidence that injection drug use does
occur in correctional settings and is associ-
ated with HIV infection. Outside the US,
intraprison spread is an important concern.
Greek researchers found that 55% of IDUs
use drugs in prisons, and over half  (57.8%)
used injection drugs. Ninety percent of those
injecting in prison shared needles, and these
researchers suggested that IDUs inject less
but share needles more frequently when
incarcerated (8). 
Very few correctional facilities allow the dis-
tribution of sterile injection equipment.
Switzerland, Spain, and Germany, however,
have had successful pilot programs and
some facilities have since adopted programs
that allow clean injection equipment to be
available.  Inmates and staff in these facili-
ties have reported that they feel safer, nee-
dle stick injuries have declined significantly,
and there was no increase in drug consump-
tion (16). In Durban, C. Menoyo presented
similar findings from a 22-month needle
exchange pilot study in the prison of Bilbao,
Spain (17). Prison officials, guards and
inmates all expressed satisfaction. No cus-
tody or safety incidents related to the pro-
gram occurred. 
Risk Behaviors: 
Unprotected Sex
Condom availability continues to be a highly
controversial topic in most correctional set-
tings.  According to the Canadian HIV/AIDS
Legal Network, all facilities in Canada and
New South Wales, Australia, and some facil-
ities in Europe allow condom distribution
within correctional settings. Condom avail-
ability is rare in facilities in the United States.  
In 1996, South Africa ended segregation of
HIV-infected prisoners and established a
policy allowing the distribution of condoms.
However, according to a report presented at
the International AIDS Conference by
Teboho Kekana of the AIDS Law Project in
South Africa, policy and practice are very far
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Country
Buenos Aires,
Argentina
(Wainstein 1998)
Rio de
Janeiro,Brazil
(Bauer TuPeD3674)
Rio de Janeiro,
Brazil (Gomes
TuPeD3690)
Women of Rio de
Janeiro, Brazil
(Carvalho
TuPeD3692)
California 
(Ruiz WePeC4343)
Cote D’Ivoire
(Togbe 1998)
Conakry, Guinea
(Magassouba
MoPeC2344)
Europe: Belgium,
France, Germany,
Italy, Portugal,
Spain, Sweden
(Rotily  TuOrD318)
India
(Ghante Nagaraj
MoPeC2333)
Nigeria(Idigbe 1998)
Russia (Morozov
MoPpC1103)
Senegal
(Ndaiye 1998)
Shanghai 
(Bao TuPeD3698)
Spain
(BurattiniTuPec3457)
United States
(Hammett 1999)
Zambia
(SimooyaMoPeC2336 )
Survey Method
voluntary Testing
voluntary
voluntary 
n=250 men, 43 women per
year
sectional study in 3 women’s
prisons=513, blood tested 
cross-sectional unlinked
(blinded) survey n=5593
random sample of 500
inmates
sample of 500, confirmed w/
western blott.
voluntary, anonymous 
questionnaire, saliva test
ELISA n=831
serostudy, random selection
of 753 inmates
mandatory, non-anonymous
testing n=4182
cross-sectional serostudy
12,998 serum samples
taken between 1991 and
1999.
random sampled 
interviewed and 
blood tested n=631
national survey
voluntary questionnaire
ELISA n=1596
HIV Prevalence
11% men
9% women
3.4% men
11.6% women
2% men 
4% women
12% women
1.43%
27.54%
3.4% overall 
3% men, 0.4%
women
5.6% overall
Portugal: 19.7%
Spain: 12.9%
1.68% women:
9.5% (mostly
CSWs)
9% 
34%
2.7%
0.23% (n=30)
16%
2.3% overall
2.3% men
(range 0.2%-
13.2%) 3.5% of
women (range
0%-20.5%)
27%
Other Notes
considered low for Brazil 
HCV 7.1%  of men,
10.1% of women
from 1996 to 1999 prevalence
did not change syphilis : 9% of
men, 20% of  women HCV: 6%
of men, 5% of women
women: 
22.6% syphilis 
23.1% HBV
10% HCV
3.5% HBsAg 34.5% HCV
77.9% were +  for anti-HSV-2
considered high in comparison
to general population
32% IDUs (n=3229) 
45% injected in prison
58% reported IDU in past 12
months
primarily among drug users
22% IDUs. 34% HCV 16%
Syphilis Parenteral exposure
was more common than sexual
Some facilities have condom
availability
no condom distribution
Table 1. International HIV in Prison Statistics
From the XIII International AIDS Conference, Durban, South Africa, July 2000
Dear Colleagues,
As horrific as the HIV epidemic has been in this country, the toll among prisoners has been even
greater.  In reports this month from the XIII International AIDS Conference in Durban, E.
Stubblefield and D. Wohl remind us that North American statistics pale in comparison to the situ-
ation in much of the developing world.  With an estimated 24.5 million adults and children living
with HIV/AIDS, Sub-Saharan Africa has 25 times the number of cases as does North America.  In
much of the developing world,. the rate of new cases and the prevalence of infection in the gen-
eral population far exceeds that seen in more developed nations.
Correctional health care providers from around the world provided data in Durban on the heavy
impact HIV is having upon the incarcerated. Ongoing injection drug use, the lack of clean nee-
dles and/or sterilizing equipment, and unprotected sex due to the unavailability of condoms cre-
ate environments in jails and prisons in developing nations by which the ongoing amplification of
the HIV epidemic is assured.
Clearly, there are success stories, both in the US and abroad. One such program at the Mysore
Central prison in India is featured this month. However, even when prisoners receive good HIV
care, many lose access once paroled or released. In California alone, over 10% of inmates are
deported upon release, usually to a resource-poor nation where access to antiretroviral therapy
is negligible.  
Certainly, progress has been made in those countries that can afford life sustaining treatments.
The challenges will be extending these benefits to the legions afflicted in developing countries,
and finding ways to stem the growing tide of new infections, which threaten to overwhelm the
efforts to control the epidemic.
This month’s issue also features a sample HIV treatment plan flowsheet and an approach to the
management of varicella zoster virus in the correctional setting. After reviewing this issue, read-
ers should be able to describe the management of chicken pox and varicella zoster virus, list ART
regimens in order of effectiveness according to the latest news from Durban, and determine when
Abacavir may be reintroduced.
As always, we welcome your feedback on HEPP News!
Sincerely,
Joseph Bick, M.D.
Letter from the Editor
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4apart. Only 3 facilities actively distribute con-
doms (18).
A recent World Health Organization (WHO)
report found that 23 of 52 countries surveyed
allowed condom distribution in their correc-
tional systems. Significantly, no system that
has adopted a policy of making condoms
available in prisons has reversed the policy,
and the number of systems that make con-
doms available has continued to grow every
year (19). According to the WHO, "condoms
should be made available to inmates through-
out their period of detention and prior to any
form of leave or release" (20).
International Recommendations:
HIV Interventions and Policies
In most countries, prisons are recognized as
key intervention sites to prevent the advance
of HIV. Reports on access to testing, medica-
tions, and trained providers in correctional
settings are limited.   Many experts and cor-
rections-related institutions, however, have
written recommendations for HIV interven-
tions in correctional settings (21). In 1993,
The World Health Organization established
broadly applicable recommendations for the 
management of HIV infected inmates (20, see
Table 2 for a summary).
In the United States, the National Commission
on Correctional Health Care (NCCHC) pro-
motes voluntary testing of prisoners and rec-
ommends the involvement of prisoners in the
development and delivery of HIV/AIDS edu-
cational programs (22). Most authors empha-
size the importance of educating staff as well
as inmates about HIV risk and the needs of
HIV infected people. The success of anony-
mous testing in one study was attributed to
the high level of HIV education in the general
prison population (2).
Even when effective HIV care is administered
in a prison setting, the gains made may be
lost following release, as was highlighted in a
presentation by Stephenson and colleagues
(23). In this retrospective study of state prison
inmates in North Carolina, HIV-infected
inmates receiving potent HIV therapies who
were released and subsequently reincarcerat-
ed were compared to matched HIV-infected
controls who remained in prison.  Released
prisoners experienced significant increases in
HIV viral loads, while those remaining in
prison  actually saw a modest decline in HIV
levels during the study period.  Clearly, these
data demonstrate that correctional facilities
indeed provide an opportunity for HIV care ini-
tiation but that community resources must
pick up where jails and prisons leave off.
Conclusion
Durban has focused the world’s attention on
the plight of the developing nations engulfed
by HIV. In many ways prisons and jails repre-
sent the best and worst of the pandemic both
in developing and developed nations. Great
strides have been made in many countries to
address HIV and AIDS in prisons and jails.
Programs enabling the distribution of con-
doms and sterile injection equipment in some
European and Australian facilities show
promise for preventing the spread of HIV.
Some U.S prisons and jails have developed
strong programs for HIV testing and treat-
ment, and many facilities conduct seropreva-
lence studies concerning HIV risk behaviors.
However, despite these successes, the failure
to implement comprehensive national pro-
grams (even in the U.S) combined with the
lack of resources from non-western countries
indicate that the global community needs
even more focus on HIV/AIDS in prisons. 
Prisons were identified years ago as key
intervention sites for identifying and treating
persons with HIV/AIDS. In 1987, prison med-
icine researcher T.W. Harding wrote:  "Prison
medical services will be tested by the AIDS
epidemic.  Prisons are not created to pro-
mote health.  Nevertheless, the AIDS epidem-
ic demonstrates forcibly how important prison
health policy is for the community as a whole"
(24).   How nations meet the challenge of pro-
viding care and preventive services in their
correctional systems remains to be seen, but
thanks to Durban, the world is now watching.
Prisons and Jails
Worldwide... 
(continued from page 2)
July/August 2000     Volume 3, Issue 7/8 visit HEPP News online at www.hivcorrections.org
Table 2. WHO Recommendations for the Management of HIV Infected Prisoners
Guidelines were established by the World Health Organization (WHO) to provide standards which corrections officials should
strive to achieve in their efforts to prevent HIV transmission and provide HIV care within correctional settings.  
The WHO recommendations are summarized as follows. The complete guidelines can be found at http://www.who.org.
G Inmates should be given the same access to and quality of HIV care that is available in the local community.  The general principles 
adopted by the national AIDS programs should apply equally to prisoners and to the community.
G All inmates and correctional staff and officers should be provided with education concerning transmission, prevention, treatment, and 
management of HIV infection.  For inmates, this information should be provided at intake and updated regularly thereafter.  HIV 
education should be part of correctional staff orientation, and should be updated regularly thereafter.
G In each country, specific policies for the prevention of HIV/AIDS in prisons and for the care of HIV-infected inmates should be defined. 
These strategies should be incorporated into a wider program of promoting health among inmates.
G Compulsory testing of inmates for HIV is unethical and ineffective, and should be prohibited.
G Voluntary testing for HIV should be available in prisons when available in the community, along with pre- and post-test counseling.
G Since segregation, isolation, and restriction on occupational activities, sports, and recreation are not considered useful or relevant in 
the case of HIV-infected people in the community, the same attitude should be adopted towards HIV-infected inmates.  Decisions on 
isolation for health conditions should be taken by medical staff only, and on the same grounds as for the general public, in accordance 
with public health standards and regulations.
G Information on the health status and medical treatment of inmates is confidential and should be recorded in files available only to health 
personnel.  If the patient consents, health personnel may provide prison managers or judicial authorities with information that will assist 
in the treatment and care of the patient.
G Inmates should have access to information on treatment options and the same right to refuse treatment as exists in the community.
G Correctional officials and public health administrators should work together to ensure medical and psychological follow-up of 
HIV-infected inmates after their release.
G Special attention should be given to the needs of women inmates.  Staff dealing with detained women should be trained to deal with 
the psychosocial and medical problems associated with HIV infection in women.
G The role of condoms in preventing HIV transmission should also be explained to inmates and staff.  Since penetrative sexual inter
course occurs in prison, even when prohibited, condoms should be made available to inmates throughout their period of detention and 
prior to any form of leave or release.
References on page 5
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Management of Varicella Zoster Exposure (Chicken Pox (CP) or Shingles)
Evaluate close contacts
Known history of CP or 
known VZV antibody positive (AB + )
Isolate patient until lesions have crusted, treat patient
Immune Obtain stat VZV serology
Unknown history of CP or 
known VZV antibody negative (AB - )
VZV IgG antibody negative VZV IgG antibody positive
Known case of CP, dermatomal or disseminated Zoster
Susceptible. If infected, will develop rash in 10-21 days
and will be contagious beginning 2 days prior to rash.
Immune
Single cell or cohort 
susceptible close con-
tacts from 8 days post
exposure until 21 days
past exposure
Put off work from 8 days post exposure until 21 days
post exposure.* If develops CP, return to work when all
lesions are crusted. Recommend follow-up with 
personal physician if immunocompromised or pregnant.
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Inmate Staff
Immunocompetant close contact Immunocompromised (HIV, malignancy,
on steroids) or pregnant
Developed by Joseph Bick, M.D., Editor, HEPP News
VZV=Varicella Zoster Virus       
VZIG=Varicella Zoster Immune Globulin
*Alternatively, assign to work in area where no contact with immunocompromised or pregnant individuals.
Consider VZIG and varicella vaccination Consider VZIG
References: (Continued from page 5.)
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Glaxo Wellcome and Merck & Co. 
1. AIDS in the world II : global dimensions,
social roots, and responses / the Global
AIDS Policy Coalition.  Ed Mann KM and
DJM Tarantola. New York : Oxford University
Press, 1996.
2. Bird AG, Gore SM, Jollife SW, Burns SM.
AIDS 1992; 6: 725-733.
3. Simooya, O. XIII International AIDS
Conference, July 2000, Durban, South Africa.
MoPeC2336
4. Togbe T. International Conference on
AIDS, 1998; 12: 1180 (abstract 60986).
5. Report on the global HIV/AIDS epidemic.
June 2000.  Available at www.unaids.org.
6. Osti NM. Mem Inst Oswaldo Cruz. 1999
Jul-Aug; 94(4): 479-83.
7. Carvalho ML. International Conference on
AIDS, 1998; 12: 454-5 (Abstract 12563).
8. Malliori M, Sypsa V, Psichogiou M et al.
Addiction, 1998; 93(2): 243-251. 
9. Rotily M, Galiner-Pujol A, Obadia Y et al.
AIDS 1994; 8: 1341-1344.
10. Martín V, Cayla JA, Morís ML et al.  Eur
J Epidemiol. 1998 Jun; 14(4): 327-31.
11. Hammett TM, Harmon P, and Maruschak
LM.  1996-1997 Update:  HIV/AIDS, STDs
and TB in Correctional Facilities.  US
Department of Justice, July 1999.  NCJ
176344.
12. Dean-Gaitor HD, Fleming PL. AIDS 1999;
13: 2429-2435.
13. Bauer, PG.  XIII International AIDS
Conference, July 2000, Durban, South
Africa.TuPeD3674. 
14. Gomes , JDS.  XIII International AIDS
Conference, July 2000, Durban, South
Africa.TuPeD3690
15. Ghante Nagaraj, S. XIII International
AIDS Conference, July 2000, Durban, South
Africa. MoPeC2333.
16. Fact sheet: HIV/AIDS in Prisons.
Prevention: Sterile Needles. Canadian
HIV/AIDS Legal Network.  Available at:
http://www.aidslaw.ca/elements/factpris-e/e-
pfact6.htm.
17. Menoyo, C. XIII International AIDS
Conference, July 2000, Durban, South Africa.
TuOrD322.
18. Kekana, T. XIII International AIDS
Conference, July 2000, Durban, South Africa.
MoPpD1039.
19. Fact Sheet: HIV/AIDS in Prisons.
Prevention: Condoms. Canadian HIV/AIDS
Legal Network.  Available at: http://www.aid-
slaw.ca/elements/factpris-e/e-pfact4.htm.
20. World Health Organization.  WHO guide-
lines on HIV infection and AIDS in prisons.
Global Program on AIDS, Geneva.  1993
March. WHO/GPA/DIR/93.3.
21. De Groot SA, Leibel SR, Zierler S.  A
standard of care for incarcerated women:
Northeastern United States’ experiences.  J
Correctional Health Care 1998; 5(2): 139-
175.
22. National Commission on Correctional
Health Care.  Management of HIV in
Correctional Facilities.  Chicago, IL. 2000.
www.ncchc.org.
23. Stephenson, B.  XIII International AIDS
Conference, July 2000, Durban, South Africa.
TuOrD323.
24. Harding TW. Lancet, 1987, Nov 28;
2(8570): 1260-1263.
6July/August 2000     Volume 3, Issue 7/8 visit HEPP News online at www.hivcorrections.org
Ask the Expert: Blistering on an August Afternoon
On Tuesday, inmate Jones presented to your clinic with a chief complaint of right sided pain in a band like distribution from his back
around to his abdomen.  Mr. Jones is HIV infected with a most recent CD-4 count of 180/mm3. He admits to malaise, but denies all
other symptoms. His exam is notable only for hyperasthesia in the painful area.  You prescribe Tylenol, and arrange follow-up. Now its
Friday afternoon, and Mr. Jones returns to your clinic with weeping vesicular lesions in the classic dermatomal pattern of zoster. Jones
lives in a dorm with 48 other HIV infected individuals.  What do you do next?
A)  Arrange for the immediate transfer of Jones to the facility that dumped on you last Friday.
B)  Decide that this is a good time to take that 2-week vacation you’ve been postponing.
C)  Relax. Read this article.
The varicella zoster virus (VZV), a herpes virus, is responsible for
primary varicella (chicken pox, CP) and recurrent disease zoster
(shingles).  In the United States, 90% of cases of CP occur in those
under the age of 13.  By early adulthood, approximately 95% have
been infected.  CP is the most contagious herpes virus, and is
spread by the respiratory route and contact with vesicular fluid.  
In children, CP is usually a benign self-limited illness, and is not
uncommonly subclinical.  The typical presentation is rash, malaise,
and three to five days of fever.  The rash is vesicular, and typically
begins on the face and trunk before spreading centrifugally. A hall-
mark of CP is the presence of successive crops of vesicles.  
In adults and especially those who are immunocompromised, CP
can be more severe with more lesions and a longer time to healing
of the lesions.  Additionally, adults and the immunocompromised
are at increased risk for bacterial infection of skin lesions, pul-
monary disease, visceral disease, and encephalitis. Once infected,
rash develops in 10 to 20 days.  Those infected are themselves
contagious from approximately 2 days before their rash develops
until all of their vesicles have crusted.  
Zoster, which is recurrent VZV disease from virus that has remained
latent in the dorsal root ganglia, afflicts at least 10% of those who
are HIV infected. The rash is typically a unilateral vesicular der-
matomal eruption, most commonly involving the thoracic and lum-
bar dermatomes. It is not uncommon for pain and paresthesias to
precede the rash by 2-3 days.  In the immunocompromised, there
is an increased risk for widespread dissemination or multi-der-
matomal involvement. The disease can be prolonged, with new
lesions occurring for up to 2 weeks and scabbing taking up to 4
weeks. Other complications include retinitis and acute retinal necro-
sis, which can be difficult to differentiate from CMV.
Treatment of CP with acyclovir can decrease new lesion formation
by one day, result in less lesions, and decrease constitutional symp-
toms in 1/3 of patients. In zoster, acyclovir decreases acute neuritis
and accelerates lesion healing.  Acyclovir is dosed at 1000 mg P.O.
five times per day for 14-21 days in adults. The pro-drugs valaci-
clovir (1000mg P.O. tid for ten days) and famciclovir (500 mg P.O.
tid for 10 days) are better absorbed and may be superior to acy-
clovir.
The infection control challenges of VZV within congregate living
environments (CLEs) such as jails and prisons are truly unique.  In
the free community, hospitalized patients who are exposed to VZV
are often discharged until their communicable period passes to
avoid transmission to other susceptibles.  In the correctional setting,
not only do we not have that option, but we often cluster our 
immunocompromised (HIV infected) inmates in CLEs where expo-
sure to zoster is likely.
Once a case of CP or disseminated zoster is diagnosed, the
American Public Health Association recommends that cases be
placed in strict isolation, preferably with negative pressure airflow.
Only staff who have positive serologies or a history of CP should be
assigned to care for these patients. In addition to an acyclovir
preparation, patients should be examined on a daily basis to assess
for complications.  Pneumonitis can initially present with tachypnea,
tachycardia, and/or dyspnea.  Patients should be kept isolated until
all lesions have crusted. 
In cases of shingles, single room placement with contact isolation is
recommended. Gowns and gloves should be used if contact with
infectious materials is expected. For both CP and zoster, contami-
nated clothing and linen should be bagged and cleaned according
to facility protocols.
Advance preparation is key.  80% of adults will recall a history of CP.
Of the remaining 20%, blood testing will reveal that all but 5% of
adults have been previously infected. By routinely obtaining varicel-
la IgG serology on all incoming immunocompromised inmates who
do not recall a history of CP, a database can be maintained of those
who are susceptible.  Ideally, serology should also be collected on
all staff who work with immunocompromised individuals and do not
remember having had CP.  Those who are found to be IgG positive
are immune. (See HEPPigram on page 5 for more information).
Now the hard part: contact investigations. If baseline serologies
have been obtained on all staff and inmates who do not recall a his-
tory of CP, your job is much simpler. If not, stat serologies should be
obtained on contacts who do not remember having had CP. Inmates
who are close contacts should be single celled from 8 days after
exposure until 20 days post exposure. If this is not possible,
exposed inmates can be cohorted in one dormitory.  Those who
develop CP should be isolated and treated as above. Non immune
staff should be reassigned so that they are not in contact with
immunocompromised individuals during their contagious period.
Close contacts who are immunocompromised are candidates for
varicella zoster immune globulin (VZIG), which must be given with-
in 96 hours to be effective.  VZIG is available from blood services
regional offices of the American Red Cross.
With appropriate planning, you can be prepared to effectively treat
CP and zoster, and prevent epidemic spread within your immuno-
compromised patients.  Education of clinical and custody staff is
essential, and will go far to help control hysteria when your next
case presents. Do it now, before that inevitable Friday afternoon
scenario!
Joseph Bick M.D., Editor, HEPP News
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Treatment Updates
Durban Continued . . .
The most important treatment news at
Durban were the comparisons between dif-
ferent HAART regimens: Triple NRTI (such
as ZDV/3TC/ABC), protease sparing
(D4T/3TC/NVP), and protease-containing
regimens were compared in several stud-
ies. There was no clear "winner" in these
studies, which underscores the importance
of providing a wide range of HIV drugs on
the correctional formulary. However, there
were some important trends. Tables 3 and 4
summarize results from three major studies,
the Atlantic study (i), the French Ecureuil
study (ii), and a Brazilian study (iii). The
data shown represents "intent to treat"
results, which count patients who do not tol-
erate the regimen and have to switch as fail-
ures.
As shown, these comparison studies
showed (1) that the three types of "Triple"
regimens used in HAART today are roughly
comparable (Atlantic study); and (2) that PI-
containing and "triple NRTI" regimens are
also roughly comparable (Ecureuil and
CNAB 3014). The Atlantic study appeared
to show that protease inhibitor (PI-) contain-
ing regimen had a slight advantage for
patients with higher initial viral loads, and
there was a statistically insignificant trend in
each of the arms towards better virologic
suppression in the PI containing regimen.
The other two studies, which were not
placebo controlled, showed slightly less
favorable results (trends only) for the PI-
containing regimens, which may be related
to study design (TID dosing of the PI). It
came as no surprise that these studies all
showed that patients with higher viral loads
had lower rates of success with any of the
regimens. Many HIV providers are consid-
ering initiating therapy with at least four
drugs in treatment-naïve patients who have
higher viral loads.
In addition, important new results on toxici-
ties believed to be related to hydroxyurea
(when used in combination with D4T and
DDI) were reported in Durban. 98 treat-
ment-naïve patients and 47 treatment-expe-
rienced patients were given DDI, D4T,
efavirenz, with or without the addition of
hydroxyurea (HU).  The study was terminat-
ed early because of a difference in neuro-
toxicity between the treatment (HU) and
placebo group (8 patients vs 2 patients). For
those patients who completed therapy, the
two regimens were equivalent, although a
trend toward better viral suppression was
observed among treatment-experienced
patients who were taking the regimen con-
taining HU. Thus, HU appears to add toxici-
ty but not benefit to regimens containing
DDI and D4T for most patients (although
other studies have shown some benefit
when DDI and HU are used in combination).
Treatment Updates from US
News Update on Abacavir
Hypersensitivity Syndrome
Glaxo Wellcome, Inc., in conjunction with
the FDA MedWatch program, released an
"important drug warning" letter last month to
inform physicians of "new safety information
about hypersensitivity reactions to aba-
cavir," or Ziagen, a nucleoside analogue
reverse transcriptase inhibitor.  In the April
1999 issue of HEPP News, we reviewed the
management of ABC-Hypersensitivity syn-
drome.  The latest letter from Glaxo warns
that "severe or fatal hypersensitivity reac-
tions can occur within hours after Ziagen
reintroduction in patients who have no iden-
tified history or unrecognized symptoms of
hypersensitivity to abacavir therapy." In fact,
in most cases, hypersensitivity occurs with-
in hours following reintroduction.  The letter
warns that if abacavir was discontinued for 
reasons not related to hypersensitivity
symptoms, the drug should only be reintro-
duced after evaluating the reason for dis-
continuation and ensuring that the patient
had no symptoms consistent with hypersen-
sitivity reactions.  If no symptoms are iden-
tified,  caution should be taken when rein-
troducing abacavir to a patient, and patients
should be educated regarding the possibili-
ty of reaction upon reintroduction and
should have access to immediate medical
care (http://www.fda.gov).
Didanosine Dosing
The preferred dosing frequency of didano-
sine (Videx) is twice daily. Once-daily
dosing should be considered only for
adult patients whose management re-
quires once-daily dosing of didanosine.
(http://www.fda.gov).
Table 3. Triple NRTI and PI vs NRTI and NNRTI*
Study
Atlantic
# patients
298
(subset)
Type of
Patient
Naive
Naive and
higher
baseline VL
(>58,000)
The study
compared
+IDV (TID)
or +NVP (QD)
or +3TC (BID)
+IDV (TID)
or +NVP (QD)
or +3TC (BID)
HIV RNA <50
at 48wks
49%
49%
40%
48%
28%
26%
Comments
P =.18
(trend)
All Patients
Received
D4T (BID) +
DDI (QD)
D4T (BID) +
DDI (QD)
*NRTI= Nucleoside Reverse Transcriptase Inhibitor 
G ABC=abacavir, ZDV=zidovudine (AZT), 3TC=lamivudine, D4T=stavudine, DDI=didanosine)
NNRTI= Non-Nucleoside Reverse Transcriptase Inhibitor 
G EFZ=efavirenz, NVP=nevirapine, DLV=delavirdine)
PI= Protease Inhibitor 
G IDV=indinavir, NLF=nelfinavir
**Both studies are expected to go 48 weeks; watch for more data.
Table 4. Triple NRTI vs NRTI + PI vs NRTI + NNRTI**
Study
Ecureuil
CNAB 
3014
# patients
195
342
(subset)
(subset)
Type of
Patient
Naïve
Naïve
Naïve and
lower base-
line VL
(<100,000)
Naïve and
higher
baseline VL
(>100,000)
The study
compared
+ ABC (BID)
or +NFV (TID)
+ ABC  (BID)
or + IDV (TID)
+ ABC  (BID)
or + IDV (TID)
+ ABC  (BID)
or + IDV (TID)
HIV RNA <50
at 48wks
67%
66%
73%
61%
82%
71%
56%
43%
Comments
Nausea and
vomiting vs
Diarrhea
All Patients
Received
Combivir
(ZDV+3TC)
Combivir
(ZDV+3TC)
Combivir
(ZDV+3TC)
Combivir
(ZDV+3TC)
References:
i   Squires, K. Abstract LbPeB7046.
ii  Brun Vezinet F, Viraben R, Malkin Abstract
WeOrB605.
iii Cahn, P. WeOrB606.
iv Murphy, R, Katlama, C, Autran, B et al
Abstract We OrB603.
Abstracts available at http://www.AIDS2000.org
24th National Conference on
Correctional Health Care 
September 9-13, 2000 
St. Louis, MO
Cervantes Convention Center 
CME credit available.
Call: 773.880.1460
Fax: 773.880.2424
Email: ncchc@ncchc.org
Visit: www.ncchc.org
HIV/AIDS Behind Bars
Saturday, Sept. 9, 2000
1:00-5:00 pm
HEPP News is sponsoring a 
pre-conference colloquium at the
NCCHC conference listed above that
will discuss the outcomes of HIV 
education and prevention interventions
in correctional settings. 
For more information 
contact Matt Stark.
Call: 401.863.2180
Fax: 401.863.1243
Email: matthew_stark@brown.edu.
Management of HIV/ AIDS in the
Correctional Setting: A Live Satellite
Videoconference Series, 
Antiretroviral Update 2000
October 3, 2000
12:30- 3:30 E.S.T.
2.5 CME credits available
Call: (518) 262-6864
Email: santosm@mail.amc.edu
Thirteenth Annual Conference
Association of Nurses in AIDS Care
Chasing a Changing Tide: Complex
Clients, Care, and Communities
November 2-5, 2000 
Caribe Hilton San Juan, Puerto Rico
Contact: Sande Gracia Jones
958 Whitehall Ln., 
Orlando , FL 33019 
Call: 305.493.6734
Fax: 305.567.4319
Email: sj394@ starnet.com 
http://www.anacnet.org/
anacabstracts.htm
Medical Management of AIDS: A
Comprehensive Review of HIV
Management - Winter Symposium 
December 7-9, 2000
San Francisco, CA
Contact: Cliff Brock
Department of Medicine UCSF
Box 0656
San Francisco, CA 94143-0656 USA
Call: 415.476.5208
Fax: 415.476.3542
Email: cme@medicine.ucsf.edu
Web: http://medicine.ucsf.edu/
programs/cme
Save the 
Dates
News Flashes
Vietnam: Increasing Number of 
HIV Cases in Prisons
HIV cases among Vietnam’s inmates have
tripled since 1998 and now comprise one-fifth of
all infections in the country, according to a gov-
ernment newspaper.  A total of 22,161 inmates
had tested HIV-positive as of July 20, with
3,621 AIDS cases and 1,895 inmate deaths
from AIDS since the first case detection in
1990.  A National AIDS Committee official said
that the actual number of HIV infections in
Vietnam’s prisons could be 10 times higher.
Infected inmates remain in the general prison
population until they develop AIDS, when they
are transferred to the prison’s clinic.  Hoping to
curb the spread of the virus, the Ministry of
Public Security last year launched an HIV/AIDS
awareness campaign in prisons and correction-
al institutions (Associated Press, 7/28).
Cost Effectiveness of Universal vs.
Voluntary Screening for HIV among
Pregnant Women Compared in
Chicago
In a recent article published in Pediatrics
Online, researchers from the University of
Illinois Chicago College of Medicine investigat-
ed the cost-effectiveness of implementing three
screening strategies to detect HIV among preg-
nant women in Chicago. The three strategies
included no screening, voluntary screening, and
universal screening. Results found that com-
pared to no screening, universal testing could
save $3.69 million for every 100,000 pregnant
women tested in Chicago. The costs of imple-
menting the program of universal testing show
that it would both lower the incidence of new-
born HIV infections and would cost less on
average per pregnant woman than no screening
or voluntary screening. (Immergluck, Lilly
Cheng; Cull, William L.; Schwartz, Alan; et al.
Pediatrics Online. April 2000; 105(4):54)
In the Works: CDC Guidelines for
TB Treatment in Prisons and Jails
The CDC is working on new guidelines for the
treatment of Tuberculosis in prisons and jails,
and will hold a meeting this Fall to finalize the
document. HEPP News will keep you updated,
or you can check with the website for the
National Center for HIV, STD and TB
Prevention at http://www.cdc.gov/nchstp/tb/ 
Ryan White CARE Act for Prison
and Jail Inmates
HRSA’s HIV/AIDS Bureau is currently working
on clarifying how Ryan White funding can be
used for programs for inmates. This is an
opportunity to let HRSA know of the myths and
barriers that you are confronting in your efforts
to utilize or access these  funds for inmate pro-
grams and discharge planning programs.  If you
have questions or suggestions, contact  John
Palenichek, Policy and Program Director,
HAB/HRSA, 5600 Fishers Lane, Rockville, MD
20857 or visit http://www.hrsa.gov/hab
Office of the Surgeon General:
Increased Involvement
The office of the Surgeon General/USPHS has
indicated that they are interested in becoming
more involved with treating HIV in men of color
and welcome community input regarding any
issues pertaining to HIV and minority men.  This
is an opportunity to let policy makers know
about HIV and corrections. To be heard, send
information to Allan Noonan, Senior Advisor,
Office of the Surgeon General /USPHS, 5600
Fishers Lane, Rockville, MD 20057 
Informational Videos:  Albany
Medical Center AIDS Program’s
Inmate Adherence Initiative
This five part videotape series models a peer
support group of five HIV-infected former
inmates.  The series addresses coping with
HIV, adherence to treatment, and related health
care issues.  The goal of the videotapes is to
improve treatment adherence, secondary pre-
vention, risk reduction, and overall enhance-
ment in the quality of life for the incarcerated
population. To order, contact Douglas Fish at
the Albany Medical College at 
518.262.6846, fax: 518.262.4756.
Resources & Opportunities
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TREATMENT WEBSITES:
HIV Insite, from UCSF "Gateway to 
AIDS Knowledge"
http://HIVInSite.ucsf.edu
HIV/AIDS Treatment Directory 
http://www.amfar.org/td
Medscape HIV/AIDS
http://hiv.medscape.com
Johns Hopkins AIDS Service
http://www.hopkins-AIDS.edu
INTERNATIONAL WEBSITES:
XIII International AIDS Conference
http://www.AIDS2000.org
AEGIS-AIDS Education Global 
Information System
http://www.aegis.com
World Health Organization
http://www.who.org
United Nations AIDS 
http://www.unaids.org
Web Resources
NEXT T CELL PROFILE
HIV - 1 / RNA / via PCR
PHYSICAL EXAM DUE
ID EVALUATION
BLOOD WORK
PPD
ANERGY PANEL
PAP SMEAR
CHEST X - RAYS
OTHER X - RAYS
THERAPEUTIC DIETS / MVI /
RESOURCE
MEDICATIONS:
ANTIRETROVIRALS
PCP PROPHYLAXIS
ANTI-FUNGAL MEDS
MAI / CRYPTO / TOXO MEDS
ANTI-VIRAL MEDS
TB MEDS
VACCINES
OTHER MEDS
CONSULTATIONS
MD / IDS SIGNATURE
NURSE SIGNATURE
Date: (example)
Q 3mo
Q 3mo
Q year
Q X weeks 
(depending on health status)
CBC, LFT, Chem 7 Q 4-6 wk
Q year
Q 6mo
Q year
MV  T PO QD
D4T, DDI, EFV
Bactrim TPOQD 
N.A.
Azithro 1200 Qwk
N.A
N.A.
DT, DV, FLV, 9/00
N.A.
A. Jaildoc, MD
Date: Date: 
Inmate Name (last, first, initial):
Sex: Race/Ethnic: Facility:
M       F                     B    W    H    O
Inmate Number: Date of Birth:
H
IV
 
1
0
1
9
HIV Treatment Plan
Developed by: HEPP News
Brown University, Box GB 426
Providence, RI 02912
www.hivcorrections.com
This plan gives overall direction to the management of each HIV patient. An example of directions, initiated by the physician and to be
administered by the nursing staff, is given on the left. This plan would be updated at least quarterly or every time there is a significant
health change in health status or medical regimen. The October 2000 issue of HEPP News will include a flow sheet on clinical HIV
management.
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Self-Assessment Test for Continuing Medical Education Credit
Brown University School of Medicine designates this educational activity for 1 hour in category 1 credit toward the AMA Physicians
Recognition Award. To be eligible for CME credit, answer the questions below by circling the letter next to the correct answer to each of
the questions. A minimum of 70% of the questions must be answered correctly. This activity is eligible for CME credit through 
Sept. 30, 2000. The estimated time for completion of this activity is one hour and there is no fee for participation.
1. Hydroxyurea may cause increased toxicity when combination
with:
a)  D4t/DDI
b)  AZT/3TC
c)  EFV/ABC
2.  In the Atlantic study reported in Durban, were the PI contain-
ing regimens significantly better than NRTI or NRTI and NNRTI
regimen?
a)  Yes, 73% of patients on the PI regimen had HIV RNA
under 50 at 48 weeks.
b)  No, only 26% of patients on the PI regimen had HIV RNA
under 50 at 48 weeks.
c)  The differences were not significant but there was a trend 
in favor of PIs at higher viral load.
3.  Which of the following phrases accurately describe Chicken
Pox in HIV-infected adults?
a)  A benign, self-limited illness
b)  Those infected risk bacterial infection of skin lesions, 
pulmonary disease, visceral disease, and encephalitis
c)  Rash is typically a unilateral vesicular dermatomal 
eruption, most commonly involving the thoracic and lum
bar dermatomes
d)  Those infected have an increased risk for widespread 
dissemination or multi-dermatomal involvement
Indicate whether the following statements are true or false:
4. Patients who have HIV should never receive varicella
zoster immune globulin, regardless of whether they are still rela-
tively immunocompetant. 
5. Inmates who are close contacts of a CP case should be
kept in single cells from 8 days after exposure to 20 days post
exposure.
6.  Under which circumstances may Abacavir be reintroduced to
a patient?
a)  After discontinuation due to symptoms of ABC 
Hypersensativity Syndrome, and carefully educating 
about potential signs and need to seek care if they 
develop.
b)  After evaluating the reasons for discontinuation and 
ensuring the patient had no signs of ABC 
Hypersensativity Syndrome.
c)  There are no circumstances under which Abacavir may 
be reintroduced after discontinuation.
BROWN UNIVERSITY SCHOOL OF MEDICINE  OFFICE OF CONTINUING MEDICAL EDUCATION  BOX G-A2  PROVIDENCE, RI 02912
The Brown University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to sponsor 
continuing medical education activities for physicians.  
The use of the Brown University School of Medicine name implies review of the educational format and material only.  The opinions, 
recommendations and editorial positions expressed by those whose input is included in this bulletin are their own.  They do not represent or 
speak for the Brown University School of Medicine.
For Continuing Medical Education credit please complete the following and mail or fax to 401.863.2660
Be sure to print clearly so that we have the correct information for you.
Name __________________________________________________________________ Degree ____________________
Address ____________________________________________________________________________________________
____________________________________________________________________________________________________
City ____________________________________________________ State ________ Zip ________________________
Telephone ________________________________________________ Fax ______________________________________
HEPP News Evaluation
5 Excellent    4 Very Good    3 Fair    2 Poor    1 Very Poor
1. Please evaluate the following sections with respect to:
educational value clarity
Main Article 5  4  3  2  1   5  4  3  2  1   
HEPPigram 5  4  3  2  1   5  4  3  2  1   
HIV 101 5  4  3  2  1   5  4  3  2  1   
Ask the
E x p e r t   5  4  3  2  1   5  4  3  2  1
Save the
Dates 5  4  3  2  1   5  4  3  2  1
2. Do you feel that HEPP News helps you in your work?
Why or why not?
3. What future topics should HEPP News address?
4. How can HEPP News be made more useful to you?
5. Do you have specific comments on this issue?
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